Evidence map›Paper›PMID 33588275›Full record

ArticleJournal of chromatography. A2021

Derivatization with 2-hydrazino-1-methylpyridine enhances sensitivity of analysis of 5α-dihydrotestosterone in human plasma by liquid chromatography tandem mass spectrometry.

Abdullah Mm Faqehi, Scott G Denham, Gregorio Naredo, Diego F Cobice, Shazia Khan, Joanna P Simpson, Ghazali Sabil, Rita Upreti, Fraser Gibb, Natalie Zm Homer and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of chromatography. A, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Abdullah Mm FaqehiUniversity/British Heart Foundation Centre for Cardiovascular Science, United Kingdom. Electronic address: a.m.m.faqehi@sms.ed.ac.uk.
Scott G DenhamMass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. Electronic address: scott.denham@ed.ac.uk.
Gregorio NaredoMass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom.
Diego F CobiceUniversity/British Heart Foundation Centre for Cardiovascular Science, United Kingdom. Electronic address: d.cobice@ulster.ac.uk.
Shazia KhanMass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. Electronic address: shazia.khan@ed.ac.uk.
Joanna P SimpsonUniversity/British Heart Foundation Centre for Cardiovascular Science, United Kingdom. Electronic address: joanna.simpson@ed.ac.uk.
Ghazali SabilUniversity/British Heart Foundation Centre for Cardiovascular Science, United Kingdom.
Rita UpretiUniversity/British Heart Foundation Centre for Cardiovascular Science, United Kingdom.
Fraser GibbUniversity/British Heart Foundation Centre for Cardiovascular Science, United Kingdom. Electronic address: fraser.gibb@ed.ac.uk.
Natalie Zm HomerMass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. Electronic address: n.z.m.homer@ed.ac.uk.
Ruth AndrewUniversity/British Heart Foundation Centre for Cardiovascular Science, United Kingdom; Mass Spectrometry Core, Edinburgh Clinical Research Facility, Queen's Medical Research Institute, University of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, United Kingdom. Electronic address: ruth.andrew@ed.ac.uk.
British Heart Foundation · GBThe Queen's Medical Research Institute · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Liquid Chromatography tandem mass spectrometry (LC-MS/MS) is the gold-standard approach for androgen analysis in biological fluids, superseding immunoassays in selectivity, particularly at low concentrations. While LC-MS/MS is established for analysis of testosterone and androstenedione, 5α-dihydrotestosterone (DHT) presents greater analytical challenges. DHT circulates at low nanomolar concentrations in men and lower in women, ionizing inefficiently and suffering from isobaric interference from other androgens. Even using current LC-MS/MS technology, large plasma volumes (>0.5 mL) are required for detection, undesirable clinically and unsuitable for animals. This study investigated derivatization approaches using hydrazine-based reagents to enhance ionization efficiency and sensitivity of analysis of DHT by LC-MS/MS. Derivatization of DHT using 2-hydrazino-1-methylpyridine (HMP) and 2-hydrazino-4-(trifluoromethyl)-pyrimidine (HTP) were compared. A method was validated using an UHPLC interfaced by electrospray with a triple quadruple mass spectrometer , analyzing human plasma (male and post-menopausal women) following solid-phase extraction. HMP derivatives were selected for validation affording greater sensitivity than those formed with HTP. HMP derivatives were detected by selected reaction monitoring (DHT-HMP m/z 396→108; testosterone-HMP m/z 394→108; androstenedione-HMP m/z 392→108). Chromatographic separation of androgen derivatives was optimized, carefully separating isobaric interferents and acceptable outputs for precision and trueness achieved following injection of 0.4 pg on column (approximately 34 pmol/L). HMP derivatives of all androgens tested could be detected in low plasma volumes: male (100 µL) and post-menopausal female (200 µL), and derivatives were stable over 30 days at -20°C. In conclusion, HMP derivatization, in conjunction with LC-MS/MS, is suitable for quantitative analysis of DHT, testosterone and androstenedione in low plasma volumes, offering advantages in sensitivity over current methodologies.

Indexed as

AdultAndrogensAndrostenedioneBiological AssayCalibrationChromatography, LiquidDihydrotestosteroneFemaleHumansHydrazinesMalePyridinesReference StandardsReproducibility of ResultsTandem Mass SpectrometryTestosterone2-hydrazino-1-methylpyridineAndrogensAndrostenedioneDihydrotestosteroneHydrazinesPyridinesTestosterone5α-DihydrotestosteroneAndrostenedioneDerivatizationLiquid chromatography mass spectrometryTestosterone

Identifiers

PMID33588275
PMCPMC7938423
OpenAlexW3124277718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.